Amgen to Webcast Investor Meeting at ASCO 2021

Rhea-AI Summary

Amgen (NASDAQ: AMGN) will host a webcast call for investors on June 4, 2021, at 4:00 p.m. ET, during the ASCO Annual Meeting. Dr. David M. Reese and the clinical development team will discuss key clinical data on the FDA-approved KRAS inhibitor LUMAKRAS™ (sotorasib), plus anti-FGFR2b antibody bemarituzumab and the bispecific T-cell engager tarlatamab. The live audio will be accessible to media, investors, and the public via Amgen's website. The recording will remain available for 90 days post-event.

THOUSAND OAKS, Calif., June 1, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss clinical data being presented on the Company's recently FDA-approved KRAS^G12C inhibitor LUMAKRAS™ (sotorasib), anti-FGFR2b antibody bemarituzumab and delta-like ligand 3-targeting half-life extended bispecific T-cell engager (BiTE^®) tarlatamab.

Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-asco-2021-301303444.html

SOURCE Amgen

FAQ

When is Amgen's webcast call at ASCO 2021?

Amgen's webcast call at the ASCO Annual Meeting is scheduled for June 4, 2021, at 4:00 p.m. ET.

Who will present during Amgen's ASCO 2021 webcast?

Dr. David M. Reese, along with Amgen's clinical development team, will present during the ASCO 2021 webcast.

What topics will Amgen discuss in the ASCO 2021 webcast?

The webcast will cover clinical data on LUMAKRAS™ (sotorasib), bemarituzumab, and tarlatamab.

Where can I access Amgen's ASCO 2021 webcast?

The webcast can be accessed on Amgen's official website under the Investors section.

How long will the ASCO 2021 webcast be available for replay?

The ASCO 2021 webcast will be archived and available for replay for at least 90 days after the event.